Hepion director Liddy Gordon reports no share holdings

Hepion Pharmaceuticals, Inc. (HEPA) reported an initial statement of beneficial ownership for director Liddy James Gordon on a Form 3.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) reported an initial statement of beneficial ownership for director Liddy James Gordon on a Form 3. The filing lists no equity transactions, derivative positions, or specific share holdings for this reporting person at the time of filing.

Key Terms

beneficial ownership, reporting person, ten percent owner, Rule 10b5-1

4 terms

beneficial ownership financial

"reported an initial statement of beneficial ownership for director"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"identifies Liddy James Gordon as a director and initial reporting person"

ten percent owner regulatory

"indicates that the reporting person is not a ten percent owner"

Rule 10b5-1 regulatory

"no specific reference to trades made under a Rule 10b5-1 plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the HEPA Form 3 filed for Liddy James Gordon disclose?

The Form 3 for Hepion Pharmaceuticals, Inc. (HEPA) identifies Liddy James Gordon as a director and initial reporting person. It shows no reported transactions, derivative positions, or specific share holdings at the time of the filing.

Does the HEPA Form 3 show any shares owned by Liddy James Gordon?

No. The Form 3 filing for Liddy James Gordon as a director of Hepion Pharmaceuticals, Inc. (HEPA) contains no reported share holdings or derivative positions in the summarized insider data.

Are there any buy or sell transactions reported in this HEPA Form 3?

No. The insider data show zero buy, sell, acquire, dispose, or other transactions for Liddy James Gordon in this Form 3 for Hepion Pharmaceuticals, Inc.

Is Liddy James Gordon a ten percent owner of HEPA according to this Form 3?

No. The Form 3 lists Liddy James Gordon as a director of Hepion Pharmaceuticals, Inc. (HEPA) and indicates that the reporting person is not a ten percent owner.

Does the HEPA Form 3 mention any Rule 10b5-1 trading plan for Liddy James Gordon?

No. The Form 3 insider data show the Rule 10b5-1 trading plan indicator as null, with no transactions reported and no specific reference to trades made under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 06:05 AM EDT Accepted by SEC EDGAR 08/21/2026 - 06:05 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liddy James Gordon

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/19/2026

3. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ James Liddy	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)